Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

Spotlight On: Next-gen JAKs carve out niche roles in myelofibrosis

google.com·10h

2026: The "Showdown Year" for Taiwan's Biotech as 10 Blockbuster Drugs Enter the Global Arena

KPTI: ASCO to feature promising phase III selinexor data in myelofibrosis and key regulatory updates

Previewing ASCO 2026: Key MPN Presentations to Watch

Treatment Selection and Monitoring Considerations for Advanced Therapies

Silence Therapeutics: Major siRNA pipeline milestones for cardiometabolic diseases ...

SENTRY and ECO42 trials highlight selinexor's promise in myelofibrosis and endometrial cancer

Incyte stock (US45337C1027): focus on dermatology and oncology pipeline after latest earnings

EHA 2026 preview – Bristol's celmod reveal | ApexOnco

Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 Views

Incyte stock (US45337C1027): focus on ruxolitinib franchise and pipeline after latest quarterly update

BTX-9341 Shows Promising Efficacy, Safety in HR-Positive, HER2-Negative Advanced ...

Protagonist Therapeutics, Inc (PTGX) Stock Price, Quote, Charts & News

CTI BioPharma Announces Oral Presentation at the 62nd American Society of Hematology Meeting

Dr Hunter on Luspatercept and Other Treatment Options for Anemia in Myelofibrosis

Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlights: Strong Revenue ...

Evolving Strategies for Myelofibrosis -Associated Anemia Highlight Persistent Gaps in ...

Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in ...

Keros Therapeutics Reports Recent First Quarter 2026 Financial Results

KPTI: Strong Q1 revenue, positive SENTRY trial results, and robust commercial outlook for 2026

Log in to enable infinite scrolling